GlassScriptPhysician profile
Kylee Nicole Pulsipher
NPI 1528609880
$4,763.93
in general payments reported to CMS, 2019-2025
26 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.50 · 2023: $771 · 2024: $1,998 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,744.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.19 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $499.89 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $435.59 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $435.23 | 2023-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $289.51 | 2023-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $284.16 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $280.92 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $280.52 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $218.72 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $209.22 | 2023-2025 | Azstarys |
| Lundbeck LLC | $192.18 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $143.34 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $139.13 | 2023-2025 | Auvelity |
| Biogen, INC. | $138.89 | 2023-2025 | Zurzuvae |
| Braeburn INC. | $84.30 | 2024-2025 | Brixadi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $82.80 | 2023-2025 | Perseris, Sublocade |
| Ironshore Pharmaceuticals INC. | $81.89 | 2023-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $75.26 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $65.25 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $34.10 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $32.28 | 2024 | Xelstrym |
| Boston Scientific Corporation | $28.46 | 2023 | |
| Supernus Pharmaceuticals, INC. | $27.25 | 2025 | Qelbree |
| Tempus Ai, INC | $25.85 | 2025 | Xt Cdx |
| Lilly USA, LLC | $20.12 | 2024 | Jardiance, Zepbound |
| Vertical Pharmaceuticals, LLC | $18.88 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylee Pulsipher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.